questionsmedicales.fr
Enzymes et coenzymes
Enzymes
Oxidoreductases
Oxidoreductases acting on CH-CH group donors
Oxidoreductases acting on CH-CH group donors : Questions médicales fréquentes
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Oxidoreductases acting on CH-CH group donors : Questions médicales les plus fréquentes",
"headline": "Oxidoreductases acting on CH-CH group donors : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Oxidoreductases acting on CH-CH group donors : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-19",
"dateModified": "2025-02-13",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Oxidoreductases acting on CH-CH group donors"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Oxidoreductases",
"url": "https://questionsmedicales.fr/mesh/D010088",
"about": {
"@type": "MedicalCondition",
"name": "Oxidoreductases",
"code": {
"@type": "MedicalCode",
"code": "D010088",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Acyl-CoA dehydrogenases",
"alternateName": "Acyl-CoA Dehydrogenases",
"url": "https://questionsmedicales.fr/mesh/D044944",
"about": {
"@type": "MedicalCondition",
"name": "Acyl-CoA dehydrogenases",
"code": {
"@type": "MedicalCode",
"code": "D044944",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682.660.150"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Cholestenone 5 alpha-reductase",
"alternateName": "Cholestenone 5 alpha-Reductase",
"url": "https://questionsmedicales.fr/mesh/D042944",
"about": {
"@type": "MedicalCondition",
"name": "Cholestenone 5 alpha-reductase",
"code": {
"@type": "MedicalCode",
"code": "D042944",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682.660.200"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Coproporphyrinogen oxidase",
"alternateName": "Coproporphyrinogen Oxidase",
"url": "https://questionsmedicales.fr/mesh/D003304",
"about": {
"@type": "MedicalCondition",
"name": "Coproporphyrinogen oxidase",
"code": {
"@type": "MedicalCode",
"code": "D003304",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682.660.250"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Dihydrodipicolinate reductase",
"alternateName": "Dihydrodipicolinate Reductase",
"url": "https://questionsmedicales.fr/mesh/D050746",
"about": {
"@type": "MedicalCondition",
"name": "Dihydrodipicolinate reductase",
"code": {
"@type": "MedicalCode",
"code": "D050746",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682.660.275"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Dihydroorotate oxidase",
"alternateName": "Dihydroorotate Oxidase",
"url": "https://questionsmedicales.fr/mesh/D004081",
"about": {
"@type": "MedicalCondition",
"name": "Dihydroorotate oxidase",
"code": {
"@type": "MedicalCode",
"code": "D004081",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682.660.300"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Dihydroorotate dehydrogenase",
"alternateName": "Dihydroorotate Dehydrogenase",
"url": "https://questionsmedicales.fr/mesh/D000090722",
"about": {
"@type": "MedicalCondition",
"name": "Dihydroorotate dehydrogenase",
"code": {
"@type": "MedicalCode",
"code": "D000090722",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682.660.313"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Dihydrouracil dehydrogenase (NAD+)",
"alternateName": "Dihydrouracil Dehydrogenase (NAD+)",
"url": "https://questionsmedicales.fr/mesh/D050744",
"about": {
"@type": "MedicalCondition",
"name": "Dihydrouracil dehydrogenase (NAD+)",
"code": {
"@type": "MedicalCode",
"code": "D050744",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682.660.325"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Dihydrouracil dehydrogenase (NADP)",
"alternateName": "Dihydrouracil Dehydrogenase (NADP)",
"url": "https://questionsmedicales.fr/mesh/D042943",
"about": {
"@type": "MedicalCondition",
"name": "Dihydrouracil dehydrogenase (NADP)",
"code": {
"@type": "MedicalCode",
"code": "D042943",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682.660.350"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Enoyl-(acyl-carrier protein) reductase (NADH)",
"alternateName": "Enoyl-(Acyl-Carrier-Protein) Reductase (NADH)",
"url": "https://questionsmedicales.fr/mesh/D050753",
"about": {
"@type": "MedicalCondition",
"name": "Enoyl-(acyl-carrier protein) reductase (NADH)",
"code": {
"@type": "MedicalCode",
"code": "D050753",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682.660.387"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Enoyl-(acyl-carrier protein) reductase (NADPH, B-specific)",
"alternateName": "Enoyl-(Acyl-Carrier Protein) Reductase (NADPH, B-Specific)",
"url": "https://questionsmedicales.fr/mesh/D050745",
"about": {
"@type": "MedicalCondition",
"name": "Enoyl-(acyl-carrier protein) reductase (NADPH, B-specific)",
"code": {
"@type": "MedicalCode",
"code": "D050745",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682.660.390"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Glutaryl-CoA dehydrogenase",
"alternateName": "Glutaryl-CoA Dehydrogenase",
"url": "https://questionsmedicales.fr/mesh/D050770",
"about": {
"@type": "MedicalCondition",
"name": "Glutaryl-CoA dehydrogenase",
"code": {
"@type": "MedicalCode",
"code": "D050770",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682.660.425"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Isovaleryl-CoA dehydrogenase",
"alternateName": "Isovaleryl-CoA Dehydrogenase",
"url": "https://questionsmedicales.fr/mesh/D050769",
"about": {
"@type": "MedicalCondition",
"name": "Isovaleryl-CoA dehydrogenase",
"code": {
"@type": "MedicalCode",
"code": "D050769",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682.660.462"
}
}
},
{
"@type": "MedicalWebPage",
"name": "3-Oxo-5-alpha-Steroid 4-Dehydrogenase",
"alternateName": "3-Oxo-5-alpha-Steroid 4-Dehydrogenase",
"url": "https://questionsmedicales.fr/mesh/D013741",
"about": {
"@type": "MedicalCondition",
"name": "3-Oxo-5-alpha-Steroid 4-Dehydrogenase",
"code": {
"@type": "MedicalCode",
"code": "D013741",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682.660.465"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Prostaglandine reductase",
"alternateName": "15-Oxoprostaglandin 13-Reductase",
"url": "https://questionsmedicales.fr/mesh/D011452",
"about": {
"@type": "MedicalCondition",
"name": "Prostaglandine reductase",
"code": {
"@type": "MedicalCode",
"code": "D011452",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682.660.490"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Prephenate dehydrogenase",
"alternateName": "Prephenate Dehydrogenase",
"url": "https://questionsmedicales.fr/mesh/D011303",
"about": {
"@type": "MedicalCondition",
"name": "Prephenate dehydrogenase",
"code": {
"@type": "MedicalCode",
"code": "D011303",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682.660.500"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Oxidoreductases acting on CH-CH group donors",
"alternateName": "Oxidoreductases Acting on CH-CH Group Donors",
"code": {
"@type": "MedicalCode",
"code": "D044925",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Wei Wang",
"url": "https://questionsmedicales.fr/author/Wei%20Wang",
"affiliation": {
"@type": "Organization",
"name": "School of Physics and Materials Science, Nanchang University, Nanchang 330031, China. ncu915@outlook.com."
}
},
{
"@type": "Person",
"name": "Hailing Li",
"url": "https://questionsmedicales.fr/author/Hailing%20Li",
"affiliation": {
"@type": "Organization",
"name": "LAPC, Institute of Atmospheric Physics, Chinese Academy of Sciences, Beijing 100029, China; University of Chinese Academy of Sciences, Beijing 100039, China."
}
},
{
"@type": "Person",
"name": "Tingting Li",
"url": "https://questionsmedicales.fr/author/Tingting%20Li",
"affiliation": {
"@type": "Organization",
"name": "LAPC, Institute of Atmospheric Physics, Chinese Academy of Sciences, Beijing 100029, China."
}
},
{
"@type": "Person",
"name": "Toshio Kasai",
"url": "https://questionsmedicales.fr/author/Toshio%20Kasai",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "King-Chuen Lin",
"url": "https://questionsmedicales.fr/author/King-Chuen%20Lin",
"affiliation": {
"@type": "Organization",
"name": ""
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "'Ironing out the risk': Assessing the effect of plateletpheresis donation frequency on iron stores in South-Asian male donors.",
"datePublished": "2023-09-29",
"url": "https://questionsmedicales.fr/article/37772675",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/vox.13525"
}
},
{
"@type": "ScholarlyArticle",
"name": "Pure laparoscopic donor right hepatectomy in patients over 50 years old: Why age should not be a barrier.",
"datePublished": "2023-09-02",
"url": "https://questionsmedicales.fr/article/37658832",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/ctr.15117"
}
},
{
"@type": "ScholarlyArticle",
"name": "Radial and ulnar forearm free flaps: A critical comparison of donor site morbidity and its impact on quality of life.",
"datePublished": "2023-08-25",
"url": "https://questionsmedicales.fr/article/37621015",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/PRS.0000000000011022"
}
},
{
"@type": "ScholarlyArticle",
"name": "Sarcopenic obesity may predict worse liver regeneration after right graft living donor liver transplantation.",
"datePublished": "2023-08-07",
"url": "https://questionsmedicales.fr/article/37548548",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/LVT.0000000000000238"
}
},
{
"@type": "ScholarlyArticle",
"name": "The Independent Effects of Kidney Length and Vascular Plaque on Ten-Year Outcomes of Extended Criteria Donor Kidney Transplants.",
"datePublished": "2023-07-14",
"url": "https://questionsmedicales.fr/article/37519905",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/ti.2023.11373"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Enzymes et coenzymes",
"item": "https://questionsmedicales.fr/mesh/D045762"
},
{
"@type": "ListItem",
"position": 3,
"name": "Enzymes",
"item": "https://questionsmedicales.fr/mesh/D004798"
},
{
"@type": "ListItem",
"position": 4,
"name": "Oxidoreductases",
"item": "https://questionsmedicales.fr/mesh/D010088"
},
{
"@type": "ListItem",
"position": 5,
"name": "Oxidoreductases acting on CH-CH group donors",
"item": "https://questionsmedicales.fr/mesh/D044925"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Oxidoreductases acting on CH-CH group donors - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Oxidoreductases acting on CH-CH group donors",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-02",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Oxidoreductases acting on CH-CH group donors",
"description": "Comment diagnostiquer une déficience en oxydoréductases ?\nQuels tests sont utilisés pour évaluer l'activité des oxydoréductases ?\nLes tests génétiques sont-ils utiles pour le diagnostic ?\nQuels symptômes peuvent indiquer un problème enzymatique ?\nComment les biomarqueurs aident-ils au diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D044925?page=1000#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Oxidoreductases acting on CH-CH group donors",
"description": "Quels sont les symptômes d'une déficience en oxydoréductases ?\nLes symptômes varient-ils selon le type d'enzyme ?\nPeut-on avoir des symptômes sans déficience enzymatique ?\nLes symptômes sont-ils toujours présents ?\nComment les symptômes évoluent-ils avec le temps ?",
"url": "https://questionsmedicales.fr/mesh/D044925?page=1000#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Oxidoreductases acting on CH-CH group donors",
"description": "Peut-on prévenir les déficiences en oxydoréductases ?\nLes dépistages sont-ils recommandés ?\nComment l'éducation peut-elle aider à la prévention ?\nLes conseils diététiques sont-ils importants ?\nLes vaccinations jouent-elles un rôle dans la prévention ?",
"url": "https://questionsmedicales.fr/mesh/D044925?page=1000#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Oxidoreductases acting on CH-CH group donors",
"description": "Quels traitements existent pour les déficiences enzymatiques ?\nLa thérapie génique est-elle une option ?\nLes médicaments peuvent-ils aider à traiter ces déficiences ?\nComment la nutrition influence-t-elle le traitement ?\nLes traitements sont-ils personnalisés ?",
"url": "https://questionsmedicales.fr/mesh/D044925?page=1000#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Oxidoreductases acting on CH-CH group donors",
"description": "Quelles complications peuvent survenir avec ces déficiences ?\nLes complications sont-elles réversibles ?\nComment les complications affectent-elles la qualité de vie ?\nLes complications peuvent-elles être évitées ?\nLes complications sont-elles fréquentes ?",
"url": "https://questionsmedicales.fr/mesh/D044925?page=1000#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Oxidoreductases acting on CH-CH group donors",
"description": "Quels sont les facteurs de risque pour ces déficiences ?\nL'âge influence-t-il le risque de déficience ?\nLes facteurs environnementaux jouent-ils un rôle ?\nLes habitudes alimentaires influencent-elles le risque ?\nLes maladies chroniques augmentent-elles le risque ?",
"url": "https://questionsmedicales.fr/mesh/D044925?page=1000#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une déficience en oxydoréductases ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests enzymatiques et des analyses biochimiques sont utilisés pour diagnostiquer."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'activité des oxydoréductases ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests spectrophotométriques mesurent l'activité enzymatique des oxydoréductases."
}
},
{
"@type": "Question",
"name": "Les tests génétiques sont-ils utiles pour le diagnostic ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les tests génétiques peuvent identifier des mutations affectant les oxydoréductases."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un problème enzymatique ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme la fatigue, des douleurs musculaires ou des troubles métaboliques peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment les biomarqueurs aident-ils au diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les biomarqueurs spécifiques peuvent indiquer une activité anormale des oxydoréductases."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une déficience en oxydoréductases ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fatigue, douleurs musculaires, troubles neurologiques et anomalies métaboliques."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon le type d'enzyme ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes dépendent du type d'oxydoréductase affectée et de son rôle métabolique."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des symptômes sans déficience enzymatique ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains symptômes peuvent être causés par d'autres conditions médicales."
}
},
{
"@type": "Question",
"name": "Les symptômes sont-ils toujours présents ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, certains patients peuvent être asymptomatiques malgré une déficience enzymatique."
}
},
{
"@type": "Question",
"name": "Comment les symptômes évoluent-ils avec le temps ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent s'aggraver avec le temps si la déficience n'est pas traitée."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les déficiences en oxydoréductases ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines déficiences peuvent être évitées par une alimentation équilibrée et des tests génétiques."
}
},
{
"@type": "Question",
"name": "Les dépistages sont-ils recommandés ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des dépistages peuvent être recommandés pour les personnes à risque génétique."
}
},
{
"@type": "Question",
"name": "Comment l'éducation peut-elle aider à la prévention ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'éducation sur les maladies métaboliques aide à reconnaître les symptômes précoces."
}
},
{
"@type": "Question",
"name": "Les conseils diététiques sont-ils importants ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des conseils diététiques peuvent aider à prévenir certaines déficiences enzymatiques."
}
},
{
"@type": "Question",
"name": "Les vaccinations jouent-elles un rôle dans la prévention ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les vaccinations ne préviennent pas directement les déficiences enzymatiques, mais protègent la santé globale."
}
},
{
"@type": "Question",
"name": "Quels traitements existent pour les déficiences enzymatiques ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des suppléments enzymatiques et des modifications diététiques."
}
},
{
"@type": "Question",
"name": "La thérapie génique est-elle une option ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la thérapie génique est explorée pour corriger certaines déficiences enzymatiques."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils aider à traiter ces déficiences ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains médicaments peuvent aider à gérer les symptômes, mais ne corrigent pas la déficience."
}
},
{
"@type": "Question",
"name": "Comment la nutrition influence-t-elle le traitement ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une nutrition adaptée peut améliorer l'état général et compenser certaines déficiences."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements sont souvent adaptés en fonction des besoins individuels du patient."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec ces déficiences ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des troubles métaboliques graves et des atteintes organiques."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles avec un traitement précoce, d'autres non."
}
},
{
"@type": "Question",
"name": "Comment les complications affectent-elles la qualité de vie ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications peuvent réduire la qualité de vie en provoquant des douleurs et des limitations fonctionnelles."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles être évitées ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un suivi médical régulier et un traitement approprié peuvent réduire les complications."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles fréquentes ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "La fréquence des complications dépend du type de déficience et de la gravité de la maladie."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour ces déficiences ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents familiaux, certaines maladies génétiques et des carences nutritionnelles sont des facteurs de risque."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque de déficience ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines déficiences peuvent se manifester plus tard dans la vie, augmentant le risque."
}
},
{
"@type": "Question",
"name": "Les facteurs environnementaux jouent-ils un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à des toxines ou à des agents environnementaux peut augmenter le risque."
}
},
{
"@type": "Question",
"name": "Les habitudes alimentaires influencent-elles le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation déséquilibrée peut contribuer à des déficiences enzymatiques."
}
},
{
"@type": "Question",
"name": "Les maladies chroniques augmentent-elles le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines maladies chroniques peuvent prédisposer à des déficiences en oxydoréductases."
}
}
]
}
]
}
Repeated blood donation is a well-known cause of iron deficiency among donors. However, present scientific literature lacks comprehensive evidence regarding the impact of regular plateletpheresis proc...
A total of 180 male participants from our platelet donor registry were enrolled in this observational cross-sectional study. Enrolment questionnaires were administered to eligible donors, and biologic...
Donors with ≥12 donations per year showed the highest prevalence of low ferritin (serum ferritin: 15-30 ng/mL) and absent iron stores (serum ferritin <15 ng/mL) (41.3% and 26.7%, respectively). Ferrit...
Regular plateletpheresis donations can lead to varying severities of non-anaemic iron deficiency. Blood centres must regularly monitor frequent plateletpheresis donors (especially donors with more tha...
Given the global aging population, the average age of liver donors is increasing. This study aimed to evaluate the surgical outcomes of grafts from pure laparoscopic donor right hepatectomy (PLDRH) in...
The medical records of liver donors were retrospectively reviewed. The donors underwent conventional donor right hepatectomy (CDRH) from January 2011 to May 2019 or PLDRH from March 2016 to May 2019. ...
Operation time (p < .01) and hospital stay (p < .01) were significantly lower in Group 1 than in Group 3. Other postoperative outcomes of donors including graft anatomical variation, graft weight, gra...
PLDRH was feasible and safe in donors aged over 50 years, with outcomes similar to those for donors aged <50 years. PLDRH should not be avoided solely based on the donor's age ≥50 years....
A poor evidence basis exists regarding direct comparing objective and subjective donor site morbidity associated with forearm flap. The authors evaluated the postoperative donor-site complications and...
All patients undergoing RFFF or UFFF harvest were included. Grip strength, pinch strength, wrist range of movement, and testing skin sensitivity were assessed with the appropriate scales at different ...
Eighty patients were enrolled (40 RFFF and 40 UFFF). The results showed a short-term reduction in grip strength, fine motor skills (tip pinch, key pinch, palmar pinch), and range of motion was observe...
Objective function limitations are reversible short-term effects after forearm flap and do not affect daily routines in the long term. Additionally, UFFF appears to be preferred over RFFF for subjecti...
Sarcopenic obesity impairs the outcome after liver transplantation. The effect of this on liver regeneration has not yet been studied. The aim of this study was to evaluate the potential effect of bod...
The independent effects of deceased donor kidney length and vascular plaque on long-term graft survival are not established. Utilizing DonorNet attachments from 4,480 expanded criteria donors (ECD) re...
A new sequential metalation strategy that enables the assembly of a new more robust reduced symmetry heterobimetallic [PdPtL...
A catalytic protio-semipinacol ring-expansion reaction has been developed for the highly enantioselective conversion of tertiary vinylic cyclopropyl alcohols into cyclobutanone products bearing α-quat...
A unique scanning protocol combining coronary computed tomography angiography (CTA) with routine abdominal CTA is being used at the Rabin Medical Center as a method of screening high-risk candidates f...
CCTA and abdominal CTA results of potential living kidney donors evaluated for donation between September 2020 and November 2021 were retrieved. A retrospective analysis of the abdominal CTA was used ...
A total of 62 potential kidney donors were evaluated for donation using the combined scan. The mean age was 53.8 years, with male predominance (59.7%). Significant coronary artery stenosis (≥70% lumin...
The use of coronary CTA in the evaluation of potential kidney donors may has a potential impact on the decision regarding eligibility for donation. A high correlation between the coronary artery calci...
Ambient air pollution has become 1 of the most important public health issues worldwide. In particular, particulate matter with an aerodynamic diameter <2.5 μm (PM...
This study was conducted on 232 kidney donors with postoperative 2-year glomerular filtration rate (GFR). The GFR was determined by serum creatinine-based method using the Modification of Diet in Rena...
Postoperative Modification of Diet in Renal Disease-estimated GFRs of kidney donors with low PM...
In patients who underwent donor nephrectomy, exposure to PM...
Despite the substantial advancements in organic solar cells (OSCs), the best devices still have quite low efficiencies due to less focus on donor molecules. With the intention to present efficient don...